The FDA and scientific priorities.

Earlier this year, when I was confirmed as the new commissioner of the US Food and Drug Administration (FDA), the world faced ongoing public health issues related to the pandemic and war in Ukraine, among other challenges. Most notably, the US is experiencing a flattening or decline in life expectancy compared with other high-income countries. As part of a wider effort to reverse this decline, relationships between FDA and the biomedical ecosystem should be reimagined to facilitate more effective translation of science into successful health interventions.

Duke Scholars

Author Robert M. Califf Medicine, Cardiology